United Kingdom (UK)
Recombinant monoclonal antibody to KRAS G12V. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody G12V-34.
Alternative Name(s) of Target: Mutated KRAS G12V; Mutated Kirsten rat sarcoma viral oncogene homolog G12V; Kirsten Rat Sarcoma virus; Kirsten Rat Sarcoma virus; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS; NS3; RALD; RASK2; K-ras; KRAS proto-oncogene; GTPase; c-Ki-ras2; OES; c-Ki-ras; K-Ras 2; 'C-K-RAS; K-Ras
Immunogen: The original antibody was generated through the construction of a phage-displayed single-chain fragment variable (scFv) library from mice splenocytes immunized with specific mimotope peptides. The library was subjected to three rounds of biopanning on G12V and G13D peptide-coated plates.
Specificity: This antibody is specific for mutated KRAS G12V.
Application Notes: The original format of this antibody (scFv) was screened against WT and mutated G12 and G13 KRAS and shown to specifically bind mKRAS G12V in an ELISA. The scFv format of this antibody was fused to mHALT-1 toxin and exhibited cytotoxic effects on SW-480 colorectal cancer cells with IC50 of 25.39 μg/mL, with minimal cytotoxicity effect on NHDF cells. The scFv format of this antibody was fused to enhanced GFP and used for IF (Teo et al., 2021; PMID: 33959410).
Antibody first published in:
Teo et al. Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated KRAS colorectal cancer cells PeerJ. 2021 Apr 15:9:e11063. doi: 10.7717/peerj.11063 PMID:33959410
Note on publication:
The original publication describes the development of a targeted therapy for KRAS-mutated colorectal cancer cells by creating a recombinant anti-mKRAS single-chain fragment variable fused with mutant Hydra actinoporin-like-toxin-1 immunotoxin.